Pituitary enlargement
(UMLS:C0877018)
- UMLS ID:
- C0877018
- MeSH ID:
- N/A
Synonym(s)
1.
Pituitary enlargement
Associated Drug(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Isotretinoin | FAERS: 5 | US FAERS | |
| 2 | Risperidone | FAERS: 5 | US FAERS | |
| 3 | Ondansetron | FAERS: 4 | US FAERS | |
| 4 | Cabergoline | FAERS: 3 | US FAERS | |
| 5 | Goserelin | FAERS: 3 | US FAERS | |
| 6 | Olanzapine | FAERS: 3 | US FAERS | |
| 7 | Buprenorphine | FAERS: 2 | OFFSIDES US FAERS | |
| 8 | Norgestrel | FAERS: 2 | OFFSIDES US FAERS | |
| 9 | Octreotide | FAERS: 2 | US FAERS | |
| 10 | Paroxetine | FAERS: 2 | US FAERS | |
| 11 | Sumatriptan | FAERS: 2 | US FAERS | |
| 12 | Dabigatran | FAERS: 1 | US FAERS | |
| 13 | Epoprostenol | FAERS: 1 | US FAERS | |
| 14 | Epoprostenol | FAERS: 1 | US FAERS | |
| 15 | Hydrocortisone | FAERS: 1 | OFFSIDES US FAERS | |
| 16 | Leuprolide | FAERS: 1 | US FAERS | |
| 17 | Leuprolide | FAERS: 1 | US FAERS | |
| 18 | Mirtazapine | FAERS: 1 | US FAERS | |
| 19 | Oseltamivir | FAERS: 1 | US FAERS | |
| 20 | Risedronic Acid | FAERS: 1 | US FAERS | |
| 21 | Thyroxine | FAERS: 1 | US FAERS | |
| 22 | Thyroxine | FAERS: 1 | US FAERS | |
| 23 | pasireotide | FAERS: 1 | US FAERS | |
| 24 | suvorexant | FAERS: 1 | US FAERS | |
| 25 | Amantadine | OFFSIDES | ||
| 26 | Carbamazepine | OFFSIDES | ||
| 27 | Cefaclor | OFFSIDES | ||
| 28 | Dexamethasone | OFFSIDES | ||
| 29 | Estradiol | OFFSIDES | ||
| 30 | Nortriptyline | OFFSIDES | ||
| 31 | Octreotide | Canada Vigilance: 1 | Canada Vigilance | |
| 32 | Pamidronate | OFFSIDES | ||
| 33 | Pregabalin | OFFSIDES | ||
| 34 | Tretinoin | OFFSIDES | ||
| 35 | Valacyclovir | OFFSIDES | ||
| 36 | oxybutynin | OFFSIDES |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120265
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.